Oral drug delivery systems developer Oramed Pharmaceuticals Inc (NASDAQ:ORMP) (TASE:ORMP) reported on Thursday the receipt of a US patent for the technology "Methods and Compositions for Oral Administration of Exenatide".
The Methods and Compositions for Oral Administration of Exenatide patent was granted by the US Patent and Trademark Office.
According to CEO Nadav Kidron, this is another important patent in the company's patent portfolio that protects a key aspect of its breakthrough technology with regard to oral Exenatide. This patent allowance comes as it is completing its phase I study with its ORMD-0901 oral Exenatide capsule under an IND in the US.
Established in 2006, the company's Protein Oral Delivery (POD) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. It is seeking to revolutionise the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes